Advisory Board
Ronald Caputo, MD, FACS, FSCAI
Director
Dr. Caputo is the Director of Cardiology Research at St. Joseph's Hospital and Assistant Clinical Professor of Medicine at SUNY-HSC, both facilities located in Syracuse, New York. In 1999, Dr. Caputo co-founded Agiolink Corporation, a Taunton, Massachusetts-based privately held medical device company focused on developing innovative wound closure solutions for vascular procedures. Medtronic, Inc. (NYSE: MDT) acquired Angiolink in November, 2004.
Dr. Caputo earned his B.S. in Biology from Georgetown University, Washington DC, in 1984 and then his MD at the Georgetown University Medical School, in 1988. Dr. Caputo is widely recognized as the country's preeminent interventionalist entrepreneur.
Steven Joseph Yakubov, M.D., FACC,FASCI
Advisor
Dr. Steve Yakubov is an interventional cardiologist, Director of the Cardiac Catheterization Laboratory at Marion General Hospital and Medical Director of the MidWest Cardiology Research Foundation, and has been involved with over 75 active clinical trials involving interventional cardiology, peripheral vascular medicine and electrophysiology. These physicians are thought leaders for their peers and contribute significant expertise and access to PanGenex.
Mark Turco MD, FACC, FSCAI
Advisor
Dr. Mark A. Turco is an interventional cardiologist with an interest in coronary and vascular diseases. Dr. Turco treats complex coronary and peripheral arterial disease patients and has an experience in interventional therapies for the treatment of adult congenital abnormalities. He is the Director of the Center of Cardiac & Vascular Research at Washington Adventist Hospital, Takoma Park, Maryland and Assistant Professor of Medicine at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. He has significant experience in clinical trial research with areas of interest including, acute coronary syndromes, interventional cardiology drugs and devices, drug eluting stents, and myocardial infarction. He has helped develop medical simulation course software for carotid intervention and complex coronary intervention and is well published in the field of cardiovascular care. Dr. Turco has helped with the development of vascular closure device technology, thrombectomy devices, new drug eluting stent platforms, and stent bifurcation technologies. He is an active member of the Society for Cardiovascular Angiography and Interventions. Dr. Turco is also the president of the Board for the local Mid Atlantic chapter of the American Heart Association.
Dr. Turco is a Philadelphia native who received his undergraduate degree from the University of Pennsylvania. He received his medical degree and Internal Medicine training at the George Washington University in Washington, DC. His Cardiology and Interventional Cardiology training were received at Temple University Hospital in Philadelphia, PA. Dr. Turco is board certified in Internal Medicine, Cardiology, and Interventional Cardiology.
Dr. Turco is the Editor of Seconds-Count’s sections titled, My Cardiovascular Care Team and I Have a Blockage in My Heart (Coronary Artery Disease).
Grant D. Carlson
Advisor
Grant D. Carlson brings over 20 years of industry experience to Calgenex and has served as President and Chief Executive Officer since founding Calgenex in February, 2006. Mr. Carlson has extensive expertise in general management, corporate and business development, product development, product launch, and sales and marketing.
Prior to founding Calgenex, Mr. Carlson was President and COO of Nanobac Pharmaceuticals, a biopharmaceutical company developing diagnostics and drug therapies for diseases associated with soft tissue calcification. Prior to joining Nanobac, Mr. Carlson was Vice President of Marketing and Business Development at Agilix Corporation, a functional genomics company developing gene expression and protein profiling technologies for biotechnology and pharmaceutical customers. Prior to joining Agilix in 2001, Mr. Carlson served as Vice President of Marketing and Business Development for Dianon Systems, Inc., a leading national anatomic pathology and genomic diagnostic services company. Dianon was ultimately sold to LabCorp for $598 million. During his 12 years at Dianon, Mr. Carlson held senior positions in marketing, business development, technology development and sales. Mr. Carlson led the launch of numerous advanced diagnostic products and biomarkers into clinical practice. He is co-inventor on five U.S. patents involving free-PSA and the diagnosis of prostate cancer. He has authored several scientific papers in the areas of oncology, urology and diagnostic pathology.
He holds a B.S. in Kinesiology from the University of California.
Louis A. Cannon, MD, FACA, FCCP, FACC, FACP
Advisor
Louis A. Cannon, MD, FACA, FCCP, FACC, FACP has been a practicing cardiologist since 1991. In 1998 he co-founded and served as president of the Michigan CardioVascular Institute in Saginaw, Michigan. In 2004 he accepted a position as the Program Director of the new Northern Michigan Hospital Heart and Vascular Institute. He has served as President of the Cardiac and Vascular Research Center of Northern Michigan, bringing over two decades of research experience using cutting edge technologies to treat cardiovascular disease.Dr. Cannon graduated from Wright State School of Medicine in Dayton, Ohio with an honorary Alpha Omega Alpha degree in 1984. He did his residency training in Akron, Ohio in a combined Internal/Emergency medicine program, becoming board certified in both. He then completed an Interventional Cardiology fellowship at the University of Cincinnati in 1991.
Dr. Cannon is a recognized leader in cardiovascular research and development. Dr. Cannon has been issued two U.S. medical patents in the field of cardiovascular treatment and was listed in the United States Top 100 Cardiovascular Specialists/Programs (Money Magazine, 2003).
Dr. Cannon is board certified in Internal Medicine, Emergency Medicine, Cardiovascular Disease, Interventional Cardiology, and is a Fellow of the American College of Cardiology, the American College of Chest Physicians, the American College of Physicians, the American College of Angiology, and the American Association of Emergency Physicians. He has been inducted into Who's Who in American Medicine and has served on the board of governors of the Michigan chapter of the American College of Cardiology.
Peter Fitzgerald, MD, PhD
Advisor
Dr. Peter Fitzgerald is the Director of the Center for Research in Cardiovascular Interventions and the Cardiovascular Core Analysis Laboratory (CCAL) at Stanford University. He has a Ph.D. in Engineering and is an interventional cardiologist. Dr. Fitzgerald has served as the Principal Investigator for over 45 clinical trials involving intravascular ultrasound. Dr. Fitzgerald has a joint appointment in the School of Medicine and Engineering. His research is focused on signal and image processing of intravascular ultrasound for plaque characterization and advanced engineering developments in signal processing and catheter device development. In addition, Dr. Fitzgerald serves as a consultant and medical/advisory board member for several biomedical device and ehealth companies in and around the San Francisco Bay Area. Dr. Fitzgerald has been principle/founder of six medical device companies in the San Francisco Bay Area. He serves on several boards of directors, advised dozens of medical device startups as well as multinational healthcare companies in the design and development of new diagnostic and therapeutic devices in Cardiology, Neurology and Orthopedics. Dr. Fitzgerald received his M.D. from Dartmouth Medical School and his Ph.D. in Biomechanical Engineering at Dartmouth College.